Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Phase 2 Completed
24 enrolled
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Phase 2 Completed
363 enrolled 16 charts
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Phase 2 Completed
11 enrolled 16 charts
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Phase 3 Completed
3,397 enrolled 24 charts
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Phase 3 Completed
2,710 enrolled 8 charts
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase 2 Completed
57 enrolled 10 charts
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Phase 3 Completed
225 enrolled 12 charts
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
Phase 1 Completed
14 enrolled
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Phase 2 Completed
36 enrolled 7 charts
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2 Completed
124 enrolled 12 charts
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
Phase 1 Completed
41 enrolled
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Phase 2 Completed
66 enrolled 7 charts
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Phase 2 Completed
39 enrolled 7 charts
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
Phase 1 Completed
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
Phase 3 Completed
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase 2/3 Completed
3,240 enrolled
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
46 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
50 enrolled
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Phase 1 Completed
24 enrolled
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
Phase 1 Completed
54 enrolled
Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer
Phase 3 Completed
800 enrolled
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase 2 Completed
75 enrolled
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Phase 2 Completed
50 enrolled
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase 2 Completed
Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase 2 Completed
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 1/2 Completed
Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer
Phase 2 Completed
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
Phase 2 Completed
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
Phase 2 Completed
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase NA Completed
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Phase 2 Completed
Oxaliplatin in Treating Patients With Liver Cancer
Phase 2 Completed
32 enrolled
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
Phase 1 Completed
84 enrolled
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Phase 2 Completed
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
Phase 1 Completed
42 enrolled
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
Phase 1 Completed
20 enrolled
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
Phase 2 Completed
40 enrolled
Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer
Phase 2 Completed
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
Phase 3 Completed
880 enrolled
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
72 enrolled
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
Phase 1/2 Completed
24 enrolled
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
Phase 3 Completed
2,472 enrolled
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
Phase 1 Completed
20 enrolled
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 3 Completed
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
Phase 2 Completed
45 enrolled
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
Phase 1 Completed
Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase 2 Completed
39 enrolled